A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.
Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D'Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY.
Sweis RF, et al. Among authors: kaiser jc.
Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1728. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39576210